IPO registrations (S-1, F-1) · Registrants
SEELOS THERAPEUTICS, INC.
- SEC CIK
- 1017491 · filings on EDGAR ↗
- Former names
- APRICUS BIOSCIENCES, INC. (2010–2019); NEXMED INC (1997–2010)
- Registration
- Form S-1, first filed 2010-08-31, last 2024-09-25; 8 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2010-09-30; declared effective 2010-09-28; withdrawal requested 2017-09-25
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 300 PARK AVENUE, 2ND FLOOR, New York, NY 10022
- EIN
- 87-0449967
- EDGAR entity type
- operating
- Insiders and CEO pay
- SEELOS THERAPEUTICS, INC. on the corporate pages
Offering terms
- Final price
- $5.40 per share (424B4 filed 2010-09-30)
- Shares sold
- 1,728,882
- Gross proceeds
- $9,335,963 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol APRI
- Lead underwriters
- Dawson James
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: SEELOS THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: SEELOS THERAPEUTICS, INC.. EXACT (EIN (EXACT))
- Form D issuer: SEELOS THERAPEUTICS, INC. EXACT (CIK (EXACT))
- SEC filer: APRICUS BIOSCIENCES, INC. EXACT (CIK (EXACT))
- Person page: Richard W Pascoe Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 45
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2010-08-31 | S-1 | S-1 (registration) | NEXMED INC | 0001144204-10-047610 ↗ |
| 2010-09-13 | S-1/A | S-1/A (amendment) | NEXMED INC | 0001144204-10-049092 ↗ |
| 2010-09-28 | S-1/A | S-1/A (amendment) | APRICUS BIOSCIENCES, INC. | 0001144204-10-051274 ↗ |
| 2010-09-28 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-10-002801 ↗ |
| 2010-09-30 | 424B4 | 424B4 (final prospectus) | APRICUS BIOSCIENCES, INC. | 0001144204-10-051603 ↗ |
| 2011-05-10 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-11-001461 ↗ |
| 2012-01-03 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-12-000048 ↗ |
| 2012-01-11 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-12-000165 ↗ |
| 2012-10-03 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-12-002889 ↗ |
| 2013-11-08 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-13-003235 ↗ |
| 2014-08-25 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-14-002600 ↗ |
| 2015-04-13 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-15-000853 ↗ |
| 2017-03-30 | S-1 | S-1 (registration) | APRICUS BIOSCIENCES, INC. | 0001017491-17-000043 ↗ |
| 2017-04-17 | S-1/A | S-1/A (amendment) | APRICUS BIOSCIENCES, INC. | 0001017491-17-000048 ↗ |
| 2017-04-20 | S-1/A | S-1/A (amendment) | APRICUS BIOSCIENCES, INC. | 0001017491-17-000060 ↗ |
| 2017-04-20 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-17-000887 ↗ |
| 2017-04-24 | 424B4 | 424B4 (final prospectus) | APRICUS BIOSCIENCES, INC. | 0001017491-17-000065 ↗ |
| 2017-09-25 | RW | RW (withdrawal request) | APRICUS BIOSCIENCES, INC. | 0001017491-17-000110 ↗ |
| 2017-10-24 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-17-002769 ↗ |
| 2017-12-07 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-17-003168 ↗ |
| 2018-04-06 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-18-000772 ↗ |
| 2018-11-20 | EFFECT | EFFECT (declared effective) | APRICUS BIOSCIENCES, INC. | 9999999995-18-002940 ↗ |
| 2019-02-13 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-19-000237 ↗ |
| 2019-02-13 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-19-000238 ↗ |
| 2019-11-21 | S-1 | S-1 (registration) | SEELOS THERAPEUTICS, INC. | 0001136261-19-000270 ↗ |
| 2019-12-02 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-19-002729 ↗ |
| 2020-01-22 | S-1 | S-1 (registration) | SEELOS THERAPEUTICS, INC. | 0001136261-20-000020 ↗ |
| 2020-01-30 | S-1/A | S-1/A (amendment) | SEELOS THERAPEUTICS, INC. | 0001136261-20-000026 ↗ |
| 2020-02-05 | S-1/A | S-1/A (amendment) | SEELOS THERAPEUTICS, INC. | 0001136261-20-000037 ↗ |
| 2020-02-07 | S-1/A | S-1/A (amendment) | SEELOS THERAPEUTICS, INC. | 0001136261-20-000041 ↗ |
| 2020-02-10 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-20-000318 ↗ |
| 2020-02-11 | 424B4 | 424B4 (final prospectus) | SEELOS THERAPEUTICS, INC. | 0001136261-20-000045 ↗ |
| 2020-11-20 | S-1 | S-1 (registration) | SEELOS THERAPEUTICS, INC. | 0001136261-20-000187 ↗ |
| 2020-12-04 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-20-003410 ↗ |
| 2020-12-23 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-20-003662 ↗ |
| 2021-12-27 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-21-004845 ↗ |
| 2023-09-29 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-23-002898 ↗ |
| 2023-12-27 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-23-003763 ↗ |
| 2024-02-02 | S-1 | S-1 (registration) | SEELOS THERAPEUTICS, INC. | 0001104659-24-009647 ↗ |
| 2024-03-06 | S-1/A | S-1/A (amendment) | SEELOS THERAPEUTICS, INC. | 0001104659-24-031555 ↗ |
| 2024-03-15 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-24-000670 ↗ |
| 2024-06-14 | S-1 | S-1 (registration) | SEELOS THERAPEUTICS, INC. | 0001140361-24-030178 ↗ |
| 2024-06-25 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-24-001952 ↗ |
| 2024-08-23 | EFFECT | EFFECT (declared effective) | SEELOS THERAPEUTICS, INC. | 9999999995-24-002619 ↗ |
| 2024-09-25 | S-1 | S-1 (registration) | SEELOS THERAPEUTICS, INC. | 0001104659-24-102540 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2010-09-28 | S-1/A | registration statement | $3.45 | - | - | 0 | primary document; price sentence | document ↗ | ||
| 2010-09-30 | 424B4 | final prospectus | $5.40 | 1,728,882 | $9,335,963 | Nasdaq APRI | 1 | primary document; price sentence, shares sentence, proceeds table, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BERMAN RICHARD J | Director; Director,Officer | President and CEO; President & Chief Executive | 15 | 2006–2010 | |
| LIU VIVIAN H | Director,Officer; Officer | CEO; Executive Vice President; Exec. V.P. and COO.; Exec. V.P., Sec. & Treas.; President and CEO | 11 | 2006–2011 | |
| Oppenheim Leonard A | Director | 32 | 2006–2014 | ||
| MO Y JOSEPH | Director | 1 | 2006 | ||
| EMIL ARTHUR D | Director | 18 | 2006–2009 | ||
| Hashim Sami A. | Director | 6 | 2006–2007 | ||
| WADE MARTIN R III | Director | 15 | 2006–2009 | ||
| Westgate Mark | Officer | Vice President and CFO; Vice President & CFO; VP &Chief Financial Officer | 6 | 2006–2010 | |
| Butts Robert W | TenPercentOwner | 4 | 2007–2008 | ||
| Clark John Smith II | TenPercentOwner | 4 | 2007–2008 | ||
| Southpoint Capital Advisors LLC | TenPercentOwner | 4 | 2007–2008 | ||
| Southpoint Capital Advisors LP | TenPercentOwner | 4 | 2007–2008 | ||
| Southpoint GP, LLC | TenPercentOwner | 4 | 2007–2008 | ||
| Southpoint GP, LP | TenPercentOwner | 4 | 2007–2008 | ||
| Tierney David S | Director | 13 | 2007–2009 | ||
| MAY JACOB | Other | 9 | 2007–2009 | ||
| Pandya Hemanshu | Officer; Other | Vice President and COO; Vice President & COO | 4 | 2007–2009 | |
| Cox Edward M. | Director,Officer; Officer | VP of Business Development; VP of Corp. Development; VP of Corp. Development and IR; VP of Corporate Development | 14 | 2009–2014 | |
| Crea Roberto | Director | 9 | 2009–2011 | ||
| Damaj Bassam | Director,Officer | Chief Executive Officer; President and CEO | 11 | 2009–2012 | |
| ESBER HENRY JEMIL | Director; Director,Officer | EVP Pre-Clinical Business Dev. | 9 | 2009–2012 | |
| Ray Rusty | Director | 22 | 2009–2018 | ||
| Gillespie Deirdre | Director | 13 | 2010–2016 | ||
| Berholtz Randy | Officer | E.V.P., General Counsel & Sec.; Executive VP & General Counsel; Executive VP, Secretary & GC | 4 | 2011–2012 | |
| Martin Steven Robert | Officer | Chief Financial Officer; Interim CEO and CFO; Interim CEO & CFO; Senior VP & CFO | 12 | 2011–2014 | |
| XANTHOPOULOS KLEANTHIS G | Director | 20 | 2011–2018 | ||
| MAIER PAUL V | Director | 12 | 2012–2018 | ||
| Pascoe Richard W | Director; Director,Officer | CEO & Secretary; Chief Executive Officer | 22 | 2013–2024 | person page Fuzzy |
| WIERENGA WENDALL | Director | 10 | 2014–2018 | ||
| SMITH SANDFORD D | Director | 10 | 2014–2018 | ||
| Dorsey Brian | Officer; Other | Chief Development Officer; SVP, Chief Development Officer | 14 | 2014–2018 | |
| Troupin Barbara | Officer | Chief Medical Officer; SVP, Chief Medical Officer | 4 | 2014–2016 | |
| Bovenizer Catherine | Officer | SVP Finance & CAO; VP Finance & CAO | 7 | 2015–2016 | |
| DENNER ALEXANDER J | TenPercentOwner | 5 | 2015–2018 | ||
| Sarissa Capital Domestic Fund LP | TenPercentOwner | 4 | 2015–2017 | ||
| Sarissa Capital Management LP | TenPercentOwner | 5 | 2015–2018 | ||
| Sarissa Capital Offshore Master Fund LP | TenPercentOwner | 4 | 2016–2018 | ||
| Morton Neil | Officer | SVP, Chief Business Officer | 12 | 2016–2019 | |
| ARMISTICE CAPITAL, LLC | TenPercentOwner | 1 | 2018 | ||
| Armistice Capital Master Fund Ltd. | TenPercentOwner | 1 | 2018 | ||
| Boyd Steven | TenPercentOwner | 1 | 2018 | ||
| Lian Brian | Director | 7 | 2019–2024 | ||
| Mehra Raj | Director,Officer; Director,Officer,TenPercentOwner | See Remarks | 11 | 2019–2024 | |
| O'Connor Daniel J. | Director | 8 | 2019–2024 | ||
| Smith Robin L | Director | 3 | 2019–2020 | ||
| Dunn Judith | Director | 3 | 2020–2021 | ||
| DALESANDRO MARGARET | Director | 6 | 2021–2024 | ||
| Golembiewski Michael Joseph | Officer | Chief Financial Officer | 9 | 2021–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-07-30 | SEELOS THERAPEUTICS, INC. | Biotechnology | $1,146,481 | $0 | 3 | 1 |
| 2024-05-31 | SEELOS THERAPEUTICS, INC. | Biotechnology | $2,042,954 | $0 | 2 | 1 |
| 2024-02-14 | SEELOS THERAPEUTICS, INC. | Biotechnology | $3,574,468 | $0 | 3 | 1 |
| 2020-09-14 | SEELOS THERAPEUTICS, INC. | Biotechnology | $5,584,950 | $0 | 13 | 1 |
| 2019-08-30 | SEELOS THERAPEUTICS, INC. | Biotechnology | $3,982,750 | $0 | 9 | 1 |
| 2017-09-27 | APRICUS BIOSCIENCES, INC. | Pharmaceuticals | $3,691,000 | $3,691,000 | 9 | 1 |
| 2016-10-13 | APRICUS BIOSCIENCES, INC. | Pharmaceuticals | $3,653,106 | $3,653,106 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | SEELOS THERAPEUTICS, INC. | NY | State business registries | name and state |
| Form D issuer | SEELOS THERAPEUTICS, INC. | NY | Form D private offerings | CIK (EXACT) |
| Patent assignee | Seelos Therapeutics, Inc. | NY | Patents (USPTO) | name and state |
| SEC filer | SEELOS THERAPEUTICS, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | SEELOS THERAPEUTICS, INC.. | EIN (EXACT) | ||
| Person page | Richard W Pascoe | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NY first:
- TG THERAPEUTICS, INC. NY
- SIGA TECHNOLOGIES INC NY
- Protagenic Therapeutics, Inc.\new NY
- XTL BIOPHARMACEUTICALS LTD NY
- PENWEST PHARMACEUTICALS CO NY
- CHEMBIO DIAGNOSTICS, INC. NY
- EYETECH PHARMACEUTICALS INC NY
- INNOVATIVE DRUG DELIVERY SYSTEMS INC NY
- EON LABS INC NY
- ORAMED PHARMACEUTICALS INC. NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health